Regeneron: III:REGN1979: A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 × ANTI-CD3BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (D
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
April 26, 2024
End Date
May 5, 2029
Administered By
Duke Cancer Institute
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
April 26, 2024
End Date
May 5, 2029